Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thionicotinamide-adenine-dinucleotide (thio-NAD or thionicotinamide-DPN) is a sulfur-containing analog of the coenzyme nicotinamide adenine dinucleotide (NAD). It is traditionally utilized as a biochemical reagent and redox indicator in enzymatic assays because its reduced form, thio-NADH, exhibits a distinct absorbance maximum at 398 nm, which is shifted from the 340 nm peak of NADH and possesses a higher molar extinction coefficient, allowing for more sensitive detection of dehydrogenase activity. Recent research has identified thionicotinamide-adenine-dinucleotide as a potential molluscicide for controlling the invasive golden apple snail (*Pomacea canaliculata*). It functions by binding to the protein neural Wiskott-Aldrich syndrome isoform X1 (PcnWAS), which leads to a decrease in the gene expression of the target and significant physiological impairment, including reduced oxygen consumption and ammonia excretion in the organism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thionicotinamide-adenine-dinucleotide.